Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MNMD
Upturn stock ratingUpturn stock rating

Mind Medicine Inc (MNMD)

Upturn stock ratingUpturn stock rating
$6.49
Last Close (24-hour delay)
Profit since last BUY-2.43%
upturn advisory
SELL
SELL since 4 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: MNMD (1-star) is a SELL. SELL since 4 days. Profits (-2.43%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

11 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $24.5

1 Year Target Price $24.5

Analysts Price Target For last 52 week
$24.5Target price
Low$4.7
Current$6.49
high$10.44

Analysis of Past Performance

Type Stock
Historic Profit 21.99%
Avg. Invested days 32
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 494.87M USD
Price to earnings Ratio -
1Y Target Price 24.5
Price to earnings Ratio -
1Y Target Price 24.5
Volume (30-day avg) 11
Beta 2.88
52 Weeks Range 4.70 - 10.44
Updated Date 06/30/2025
52 Weeks Range 4.70 - 10.44
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.75

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -25.84%
Return on Equity (TTM) -37.07%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 305224424
Price to Sales(TTM) -
Enterprise Value 305224424
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -6.57
Shares Outstanding 75553296
Shares Floating 70711057
Shares Outstanding 75553296
Shares Floating 70711057
Percent Insiders 0.85
Percent Institutions 55.18

Analyst Ratings

Rating 4
Target Price 24.5
Buy 4
Strong Buy 7
Buy 4
Strong Buy 7
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Mind Medicine Inc

stock logo

Company Overview

overview logo History and Background

Mind Medicine (MindMed) Inc. was founded in 2019. It's a biotechnology company focused on discovering, developing, and deploying psychedelic-inspired medicines and therapies to address addiction and mental health. It went public in 2020 and has pursued clinical trials and partnerships to advance its pipeline.

business area logo Core Business Areas

  • Drug Development: Developing novel psychedelic-inspired therapeutics for psychiatric disorders and substance abuse.
  • Clinical Trials: Conducting clinical trials to assess the safety and efficacy of its drug candidates.

leadership logo Leadership and Structure

Robert Barrow is the CEO. The company has a structured management team overseeing drug development, clinical operations, and business strategy. They have a Board of Directors that manages overall governance and strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • MM-120 (Lysergide D-Tartrate): MM-120 is MindMed's lead drug candidate, a synthetic form of LSD being developed for Generalized Anxiety Disorder (GAD). It's currently in Phase 2b trials. Market share data is not currently available as it is pre-commercialization. Competitors include companies developing treatments for GAD and other mental health disorders. These treatments include SSRIs, SNRIs, and traditional therapeutic options.
  • MM-402: MM-402 is an R-enantiomer of MDMA, being developed as a potential treatment for autism spectrum disorder (ASD). It aims to offer the positive effects of MDMA, such as increased sociability, without the potential negative effects. It is pre-clinical and has no market share or revenues. Potential competitors are companies that develop medicines or therapies for autism spectrum disorder, which is largely a non-pharmaceutical treatment market currently.

Market Dynamics

industry overview logo Industry Overview

The psychedelic medicine industry is an emerging field focused on developing therapies based on psychedelic compounds for mental health and addiction. It is attracting increasing investment and regulatory interest.

Positioning

MindMed is a key player in the psychedelic medicine industry, focusing on rigorous clinical trials and drug development. It aims to differentiate itself through scientific validation and regulatory approval of its products.

Total Addressable Market (TAM)

The TAM for mental health treatments, including anxiety, depression, and addiction, is estimated to be billions of dollars annually. MindMed is positioned to capture a share of this market if its therapies are approved and successfully commercialized.

Upturn SWOT Analysis

Strengths

  • Strong intellectual property portfolio
  • Experienced leadership team
  • Focus on rigorous clinical trials
  • Early mover advantage in the psychedelic medicine industry

Weaknesses

  • High cash burn rate
  • Dependence on regulatory approvals
  • Limited revenue stream
  • Relatively new company with limited historical performance data

Opportunities

  • Growing acceptance of psychedelic therapies
  • Potential for breakthrough therapies for unmet medical needs
  • Strategic partnerships with pharmaceutical companies
  • Expansion into new indications and markets

Threats

  • Regulatory hurdles and uncertainty
  • Competition from other companies in the psychedelic medicine industry
  • Potential for adverse events in clinical trials
  • Negative public perception of psychedelics

Competitors and Market Share

competitor logo Key Competitors

  • ATAI
  • COMP

Competitive Landscape

MindMed competes with other biotech companies focused on psychedelic-assisted therapies. The competitive landscape is characterized by a race to secure intellectual property, advance clinical trials, and obtain regulatory approvals. As a pre-revenue company, it is very difficult to calculate market share. All companies in the field are trying to create their individual markets.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is represented by advancement of drugs through clinical trial phases and partnerships.

Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its drug candidates. Analyst estimates vary widely due to the uncertain nature of the industry.

Recent Initiatives: Recent initiatives include the initiation and continuation of clinical trials for MM-120 and MM-402, and partnerships with academic institutions.

Summary

MindMed is a high-risk, high-reward biotechnology company operating in the emerging psychedelic medicine industry. Its success depends on the successful completion of clinical trials and regulatory approvals. The company needs to manage its cash burn rate effectively and capitalize on opportunities to establish a strong market position. Competition and regulatory hurdles remain significant challenges.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • MindMed Investor Relations
  • SEC Filings
  • Analyst Reports

Disclaimers:

The data provided is for informational purposes only and should not be considered investment advice. The psychedelic medicine industry is highly speculative, and investments are subject to significant risk. Market Share is difficult to calculate because the market is pre-commercialization.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Mind Medicine Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2020-03-03
CEO & Director Mr. Robert Barrow
Sector Healthcare
Industry Biotechnology
Full time employees 74
Full time employees 74

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.